Superior risankizumab efficacy vs. apremilast in systemic-eligible moderate psoriasis.

Amongst people w/ psoriasis, does exposure to Risankizumab ... (Yiu, SOS Challenge Presentation)Подробнее

Risankizumab shows promise for PsA in the KEEPsAKE 2 trial | Andrew OstorПодробнее

Lecture-120: Introduction to Apremilast in PsoriasisПодробнее

Ixekizumab vs. guselkumab in plaque psoriasis, A. Blauvelt et alПодробнее

Plaque Psoriasis: UltIMMA and Other TrialsПодробнее

Psoriasis: Translating Current and Emerging Therapies into Enhanced Management StrategiesПодробнее

Risankizumab for PsA: How will the KEEPsAKE 1 & 2 findings impact clinical practice? | Laura CoatesПодробнее

Ken Gordon, MD: Clinical Implications of the UltIMMa Trials of RisankizumabПодробнее

FDA Approves Label Update to Include Additional Data for Otezla ® (apremilast)Подробнее

Risankizumab Safe, Effective in Moderate to Severe Crohn's Disease - Medpage TodayПодробнее

New Data Demonstrates Potential for Oral IL-23 in PsoriasisПодробнее

Treatment of psoriasis - new small moleculesПодробнее

IL-23 Inhibitors and Other Emerging Psoriasis TreatmentsПодробнее

Risankizumab vs. Ustekinumab for PsoriasisПодробнее

Uptake of biosimilars for psoriasis, D.B. Phan, et alПодробнее

Innovations in Systemic Treatments for Psoriasis | Andrew Blauvelt, MD, MBA | United StatesПодробнее

Risankizumab worsened symptoms in patients with severe asthma, new study findsПодробнее

lxekizumab Reduces key IL-17 and IL-23 Pathway Genes More Rapidly than Guselkumab | Lam Tsoi, PhDПодробнее

If you take Skyrizi pls lmk! #skyrizi #psoriasis #psoriaticarthritis #psoriasistreatmentПодробнее